Orum Therapeutics, Inc.

As of June 30, 2026, Orum Therapeutics, Inc. has 21.23M shares outstanding.

As of June 30, 2026, Orum Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 69.54. The price-to-sales ratio is 31,741.42, and the price-to-book ratio stands at 6.76.

These figures are as of June 30, 2026. The EV/Sales ratio of 27,155.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2026, Orum Therapeutics, Inc. maintains a current ratio of 3.12, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 51.72, indicating elevated leverage, while an interest coverage ratio of -34.72 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Orum Therapeutics, Inc. posted a return on equity (ROE) of 10.79, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -28.29, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 7.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.80, useful for judging operating efficiency across full business cycles.

As of the close on October 23, 2026, Orum Therapeutics, Inc.'s stock has declined approximately 54.26% over the past 52 weeks. The 50-day moving average sits at 43,483.20, while the 200-day moving average is 76,713.30.

Over the twelve months ended June 30, 2026, Orum Therapeutics, Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -161,817.90 and net profit margin of 45,646.45 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.82, meaning Orum Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Orum Therapeutics, Inc. has an Altman Z-Score of 7.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.